Program
brincidofovir
Also written as “Brincidofovir”, “CMX001” and “SyB V-1901”.
Its studies are mostly in Adenoviridae Infections · Cytomegalovirus Infections · Lymphoma, T-Cell · Smallpox · Kidney Diseases, led by 3 companies.
Drug pageBrincidofovir: every studyAll 22 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Jazz Pharmaceuticals | 140 open or running | phase 3since Jun 11, 2010 | Oct 23, 2008 | none ahead |
| SymBio Pharmaceuticalsits history only | 41 open or running | phase 3since Jan 20, 2026 | Aug 29, 2020 | Jan 31, 2028phase 3 · NCT07387367 |
| Emergent BioSolutionsits history only | 10 open or running | phase 1since Jun 5, 2023 | Jun 5, 2023 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Jazz Pharmaceuticals only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 23, 2008First study: phase 1 study in HealthyFirst studyNCT00780182 · 24 enrolled · United States
- Nov 17, 2008Phase 2 study in ViruriaNCT00793598 · 29 enrolled · United States
- Jul 17, 2009Phase 2 study in Cytomegalovirus InfectionsNCT00942305 · 239 enrolled · United States
- Jun 11, 2010Phase 3 study in Adenoviridae InfectionsNCT01143181 · 210 enrolled · United States
- Nov 12, 2010Phase 2 study in Adenovirus DiseaseNCT01241344 · 52 enrolled · United States
- Jun 30, 2011Phase 1 study in Hepatic ImpairmentNCT05391724 · 25 enrolled · United States
- Jan 14, 2013Phase 3 study in CMVNCT01769170 · 452 enrolled · United States, Belgium, Canada
- Mar 12, 2014Phase 3 study in Adenoviridae InfectionsNCT02087306 · 201 enrolled · United States
- Oct 7, 2014Phase 2 study in Ebola VirusNCT02271347
- May 7, 20152 phase 3 studies in Cytomegalovirus InfectionsNCT02439970, NCT02439957
- Nov 8, 2017Phase 2 study in Adenoviridae InfectionsNCT03339401 · 29 enrolled · United States, France, Germany and more
- Apr 26, 2018Phase 2 study in Adenoviridae InfectionsNCT03532035 · United States, Italy, Spain
- Feb 12, 2020Phase 2 study in Hemorrhagic Fever, EbolaNCT04268966
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
“DNA polymerase inhibitor”ChEMBL 37, by rule
Studies
All 14 Jazz Pharmaceuticals leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT04268966Hemorrhagic Fever, Ebola | 2 | Withdrawn | Nov 2015 | 0 |
| NCT03532035Adenoviridae Infections · United States, Italy, Spain | 2 | Withdrawn | May 10, 2019 | 0 |
| NCT03339401Adenoviridae Infections · United States, France, Germany and more | 2 | Terminated | May 10, 2019 | 29 |
| NCT02439970Cytomegalovirus Infections · United States | 3 | Terminated | Jan 30, 2016 | 5 |
| NCT02439957Cytomegalovirus Infections · United States | 3 | Terminated | May 15, 2016 | 6 |
| NCT02271347Ebola Virus | 2 | Withdrawn | Jan 2015 | 0 |
| NCT02087306Adenoviridae Infections · United States | 3 | Completed | Jun 2016 | 201 |
| NCT01769170CMV · United States, Belgium, Canada | 3 | Completed | Dec 2015 | 452 |
| NCT05391724Hepatic Impairment · United States | 1 | Completed | Sep 2011 | 25 |
| NCT01241344Adenovirus Disease · United States | 2 | Completed | Jun 2013 | 52 |
| NCT01143181Adenoviridae Infections · United States | 3 | Completed | Dec 2012 | 210 |
| NCT00942305Cytomegalovirus Infections · United States | 2 | Completed | Jan 2012 | 239 |
| NCT00793598Viruria · United States | 2 | Completed | Oct 2010 | 29 |
| NCT00780182Healthy · United States | 1 | Completed | Dec 2008 | 24 |
How it is read
Names in the registry
- “Brincidofovir”, 15 entries
- “CMX001”, 3 entries
- “SyB V-1901”, 1 entry
Conditions, from the studies’ own filings
- Adenoviridae Infections, 5 studies
- Cytomegalovirus Infections, 3 studies
- Lymphoma, T-Cell, 1 study
- Smallpox, 1 study
- Kidney Diseases, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.